Technology evaluation: rh lactoferrin, Agennix.
Agennix is developing recombinant human (rh) lactoferrin, a glycoprotein with antibiotic, anti-inflammatory and immunomodulatory activity, for the potential treatment of cancers, asthma and chronic wounds. rh Lactoferrin is currently undergoing phase II clinical trials.
Andersen
Jeanette H
JH
University Hospital of North Norway, Department of Medical Microbiology, Tromso N-9038, Norway. jeanettea@nfh.uit.no
D001230:Aspergillus / Q000235:genetics; D001249:Asthma / Q000188:drug therapy*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D007781:Lactoferrin / Q000235:genetics / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000235:genetics / Q000493:pharmacokinetics / Q000627:therapeutic use; D014945:Wound Healing / Q000187:drug effects*; D014947:Wounds and Injuries / Q000188:drug therapy*
D011994:Recombinant Proteins; D007781:Lactoferrin